Is long-term virological response related to CCR5 Δ32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?

HIV Medicine

Volumn 11, Issue 4, 2010, Pages 239-244

  Laurichesse, J J ^a   Taieb, A ^b   Capoulade Metay, C ^c   Katlama, C ^c   Villes, V ^b   Drobacheff Thiebaud, M C ^d   Raffi, F ^e   Chene G ^b   Theodorou, I ^c   Leport, C ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Antiretroviral therapy; CCR5 32 deletion; HIV; Virological response

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CYSTEINE; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EXPOSURE; FEMALE; GENE DELETION; GENETIC ASSOCIATION; HETEROZYGOTE DETECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN MOTIF; TREATMENT DURATION; TREATMENT RESPONSE; WILD TYPE;

ADULT; AGE FACTORS; ALLELES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GENE DELETION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RECEPTORS, CCR5; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77950836637     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00769.x     Document Type: Article

References (20)

1. Samson M, Libert F, Doranz BJ. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
2. Ioannidis JP, Rosenberg PS, Goedert JJ. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001, 135:782-795.
3. Meyer L, Magierowska M, Hubert JB. Early protective effect of CCR5 Δ32 heterozygosity on HIV-1 disease progression: relationship with viral load. AIDS 1997, 11:F73-F78.
4. de Roda Husman AM, Koot M, Cornelissen M. Association between CCR5 genotype and the clinical course of HIV-1 virus infection. Ann Intern Med 1997, 127:882-890.
5. Meyer L, Magierowska M, Hubert JB. CCR5 Δ32 deletion and reduced risk of toxoplasmosis in HIV-1 infected patients. J Infec Dis 1999, 180:920-924.
6. Mocroft A, Devereux H, Kinloch-de-Loes S. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000, 4:1545-1552.
7. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001, 15:2251-2257.
8. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5 delta32 mutation with improved response to antiretroviral therapy. JAMA 1999, 8:734.
9. Yamashita TE, Phair JP, Munoz A. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001, 15:735-746.
10. Kasten S, Goldwich A, Schmitt M. Positive influence of the Δ32 CCR5 allele on response to highly active antiretroviral therapy (cART) in HIV-1 infected patients. Eur J Med Res 2000, 5:323-328.
11. Bogner JR, Lutz B, Klein HG, Pollerer C, Troendle U, Goebel FD. Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type. HIV Med 2004, 5:264-272.
12. O'Brien TR, McDermott DM, Ioannidis JP. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. AIDS 2000, 14:821-826.
13. Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998, 12:2193-2202.
14. Brumme ZL, Chan KJ, Dong W. CCR5 Δ32 and promoter polymorphism are not correlated with initial virological or immunological treatment response. AIDS 2001, 15:2259-2266.
15. Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuitemaker H. CC chemokine receptor 5 Δ32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immuodeficiency virus type 1-infected patients. J Infec Dis 2002, 186:1726-1732.
16. Guerin S, Meyer L, Theodorou I. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2000, 14:2788-2790.
17. Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. HIV Med 2007, 8:213-219.
18. Le Moing V, Thiébaut R, Chêne G. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002, 185:471-480.
19. Lewden C, Chene G, Morlat P. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007, 46:72-77.
20. Carrieri MP, Raffi F, Lewden C. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther 2003, 8:585-594.